Effects of Mifepristone on Nonalcoholic Fatty Liver Disease in a Patient with a Cortisol-Secreting Adrenal Adenoma

Table 1

Baseline patient characteristics and laboratory findings.

Parameter	Result
Age, years	49
BMI, kg/m^2	30.6
BP, mmHg	142/90
HbA1c, mmol/mol	41
Lipids, mmol/L
Total cholesterol	7.1
LDL	5.3
TG	1.5
Liver function
AST, U/L (normal 2–40)	110
ALT, U/L (normal 2–60)	232
Endocrine evaluation
UFC, nmol/d (normal 11–138)	172.8
1-mg DST, nmol/L (normal < 49.5)	364.3; 345.0
Late night salivary cortisol, nmol/L; (normal < 2.5)	5.2
ACTH, pmol/L (normal 1.1–9.9)	<1.1 × 2
DHEA-S, μmol/L (normal 1.1–7.9)	0.54

ACTH, adrenocorticotropic hormone; ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; BP, blood pressure; DHEA-S, dehydroepiandrosterone sulfate; DST, dexamethasone suppression test; HbA1c, glycated hemoglobin A1c; LDL, low-density lipoprotein; TG, triglyceride; UFC, urinary free cortisol.